Parliamentary Search

Written question asked by Baroness Masham of Ilton (Crossbench) on Tuesday, 5 December 2017, in the House of Lords. It was due for an answer on Tuesday, 19 December 2017. It was answered by Lord O'Shaughnessy (Conservative) on Wednesday, 13 December 2017 on behalf of the Department of Health.

European Medicines Agency

Question

To ask Her Majesty's Government what assessment they have made of the impact on the safety of clinical trials and new medicines of the European Medicines Agency's re-location to the Netherlands.

Answer

We recognise the important role that the European Medicines Agency (EMA) plays in the protection of human health.

In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of clinical trials and medicines regulation in the best interests of both the United Kingdom and the EU. The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the UK remains one of the best places in the world for science and innovation. Regardless of the outcome of those negotiations the UK is committed to offering a competitive service for clinical trial assessment.

Following the EMA's relocation to the Netherlands our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.

Secondary information

Type
Written question
Reference
HL3899
Session
2017-19
Grouped for answer
Yes
Subjects
Drugs Location Safety Clinical trials European Medicines Agency Brexit
Link
View this Written question on www.parliament.uk